Presentations and Posters
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
ESMO, 2023 Oct, Madrid Spain (ポスター)
ESMO
Pertuzumab retreatment in patients with HER2-positive locally advanced/ metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Naruto Taira, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda
ASCO, 2023 Jun, Chigago USA (Poster Discussion Session)
ASCO
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Kenichi Inoue, Norikazu Masuda, Toshimi Takano, Mitsuya Ito, Yuko Tanabe, Kosuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R. Kataoka, Satoshi Morita, Masakazu Toi
ESMO Breast Cancer, 2023 May, Berlin Germany (Mini Oral)
ESMO
Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Kaho Utsunomiya, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2022.12 SABCS Poster San Antonio, Texas
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer Initial Results from the POSITIVE Trial
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Sætersdal, Judith R Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
SABCS, 2022 Dec, Texas USA (Oral)
SABCS
Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takeshi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
2022.9 ESMO Poster WEB
Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2‐positive primary breast cancer: Neo-LaTH (JBCRG-16) study.
Tomomi Fujisawa, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Eriko Tokunaga, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu, Katsumasa Kuroi, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi
2021.9 ESMO Poster WEB
Genomic profile and response prediction of eribulin mesylate based neoadjuvant chemotherapy in triple negative breast cancer patients
Tomomi Nishimura, Norikazu Masuda, Kosuke Kawaguchi, Masahiro Takada, Yurina Maeshima, Sunao Tanaka, Ravindranath M. Velaga, Yuichiro Kikawa, Takayuki Kadoya, Hiroko Bando, Rikiya Nakamura, Yutaka Yamamoto, Takayuki Ueno, Hiroyuki Yasojima, Hiroshi Ishiguro, Satoshi Morita, Shinji Ohno, Hironori Haga, Seishi Ogawa, Masakazu Toi
2021.9 ESMO Poster WEB
Immune microenvironment, homologous recombination deficiency and therapeutic response
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Takayuki Kadoya, Hiroko Bando, Takashi Yamashita, Shoichiro Ohtani, Shigenori Nagai, Takahiro, Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
2021.9 ESMO Poster WEB
Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (Translational Research of the JBCRG-22 Trial)
Kosuke Kawaguchi, Norikazu Masuda, Sunao Tanaka, Hiroko Bando, Tomomi Nishimura, Takayuki Kadoya, Takashi Yamanaka, Shigeru Imoto, Ravindranath M. Velaga, Nobuko Tamura, Tomoyuki Aruga, Yurina Maeshima, Masahiro Takada, Eiji Suzuki, Takayuki Ueno, Seishi Ogawa, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi
2021.9 ESMO Poster WEB
by Voluntary Organization JBCRG